Skip to content

Research on the role and mechanism of PANoptosis in sarcopenia

Research on the role and mechanism of PANoptosis in sarcopenia

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500096021
Enrollment
Unknown
Registered
2025-01-16
Start date
2025-03-01
Completion date
Unknown
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sarcopenia

Interventions

A:Male patients aged 20-40 years (well nourished, BMI 18.5-23.9 kg/m2) who require open reduction and internal fixation surgery for upper femoral fractures
B:Elderly male patients aged 65 years and above who do not suffer from muscle atrophy and require femoral head replacement for hip fractures
C:Elderly male patients over 65 years old with sarcopenia who require femoral head replacement for hip fractures.

Sponsors

Fujian Fuqing Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients who visited the Department of Orthopedics at Fuqing Hospital from January 1, 2024 to May 30, 2023. Grouping: Group A (n=12): Male patients aged 20-40 years (well nourished, BMI 18.5-23.9 kg/m2) who require open reduction and internal fixation surgery for upper femoral fractures; Group B (n=12): Elderly male patients aged 65 years and above who do not suffer from muscle atrophy and require femoral head replacement for hip fractures; Group C (n=12): Elderly male patients over 65 years old with sarcopenia who require femoral head replacement for hip fractures.

Exclusion criteria

Exclusion criteria: Pathological fracture, combined with other organ injury or fracture at other parts, previous operation affecting the lateral thigh muscle structure, tumor disease, rheumatic disease, diabetes, myopathy or other neuromuscular disease history, chronic virus infection (hepatitis B virus [HBV], hepatitis C virus [HCV], human immunodeficiency virus [HIV], etc.); Taking anti osteoporosis drugs or long-term corticosteroid treatment for autoimmune diseases (more than one month); Injury lasting more than 3 days; Elderly individuals who have not undergone chest CT scans; Patients who do not agree to participate in this experiment.

Design outcomes

Primary

MeasureTime frame
TNF-a and IL-6;panoptosis;

Countries

China

Contacts

Public ContactHengting Chen

Fujian Fuqing Hospital

13612022165@163.com+86 136 1202 2165

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026